The rapid development of new COVID-19 vaccines and treatments over the past year is a triumph of innovation. Billions of vaccine doses are being manufactured and should be distributed to all adults globally over the next 18 months. But some argue that suspending intellectual property (IP) rights to allow any company to manufacture vaccines will mean faster access for developing countries. These arguments have culminated in a proposal at the World Trade Organization for a temporary global waiver on COVID-19-related IP rights.
Please join Fundacion IDEA and Geneva Network for a discussion on the role of IP rights in vaccine and therapeutic R&D, manufacturing, and preparedness for future pandemics. Panelists from around the world will discuss the best ways to scale up the mass vaccine and therapeutic manufacturing and examine the implications that would arise from a global waiver of IP rights.
The confirmed panelists for the session are presented below:
- Mariana Gonzalez, Partner at Becerril, Coca y Becerril. Partner at VALAE Legal Group International. Lawyer and Chemist by the Universidad Autónoma de México.
- Mark Schultz, Professor at University of Akron School of Law, Goodyear Tire & Rubber Chair in Intellectual Property Law, United States.
- Yogesh Pai, Co-Director of Centre for Innovation, Intellectual Property and Competition (CIIPC) at National Law University Delhi, and IPR Chair at NLU Delhi established by the Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India.
- Moderator: Carolina Agurto, Partner at Fundación IDEA, Mexico.
The webinar will take place on August 10th, 2021, from 12:00 pm to 13:15 pm (GMT-5).
The session will be held in English and Spanish, with the option of simultaneous translation.